Evidence map›Paper›PMID 33878180›Full record

ArticleRheumatology (Oxford, England)2022

Patients with early-onset primary Sjögren's syndrome have distinctive clinical manifestations and circulating lymphocyte profiles.

Lin Wei, Xin Zhifei, Ning Xiaoran, Liu Meilu, Li Yang, Liu Yixuan, Ren Xiuying, Su Yashuang, Cao Jingjing, Guo Shaoying and 4 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Epidemiology of Sjögren syndrome.Nature reviews. Rheumatology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Lin WeiDepartment of Rheumatology and Immunology.
Xin ZhifeiDepartment of Thoracic Surgery.
Ning XiaoranDepartment of Rheumatology and Immunology.
Liu MeiluDepartment of Rheumatology and Immunology.
Li YangDepartment of Oncology, Hebei General Hospital.
Liu YixuanDepartment of Rheumatology and Immunology.
Ren XiuyingDepartment of Rheumatology and Immunology.
Su YashuangDepartment of Rheumatology and Immunology.
Cao JingjingDepartment of Rheumatology and Immunology.
Guo ShaoyingDepartment of Graduate School, Hebei Medical University, Shijiazhuang, China.
Yang LiuDepartment of Graduate School, Hebei Medical University, Shijiazhuang, China.
Sun LijunDepartment of Rheumatology and Immunology.
Zhang FengxiaoDepartment of Rheumatology and Immunology.
Zhang WenDepartment of Rheumatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Hebei Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHebei General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo further investigate the clinical characteristics and circulating lymphocyte profiles of patients with early-onset primary Sjögren's syndrome (pSS).

methodData of 333 patients with pSS were analysed retrospectively. Early onset was defined as a pSS diagnosis at an age of 35 years or younger. The clinical, laboratory and immunophenotypic profiles of peripheral blood lymphocyte subsets were compared between early- and later-onset pSS.

resultsThirty-six (10.81%) patients matched the definition of early-onset pSS, with age at disease onset being 28.97  (5.53) years. Elevated serum IgG level (77.14% vs 31.16%, P <0.001), low C3 (41.67% vs 20.20%, P =0.004) and C4 levels (27.78% vs 6.40%, P <0.001), anti-SSA positivity (91.67% vs 51.85%, P <0.001) and anti-SSB positivity (50% vs 20.54%, P <0.001) were more frequent in early-onset patients. The frequencies of hematological (80.56% vs 52.53%, P =0.001), renal (19.44% vs 5.05%, P =0.005) and mucocutaneous involvement (50% vs 22.56%, P <0.001) were significantly higher in the early-onset pSS group, which showed a higher 2010 EULAR SS Disease Activity Index (ESSDAI) [11(6.25-17) vs 7(3-12); P =0.003], compared with the later-onset group. In addition, profound CD4+ T-cell lymphopenia was found in patients with early-onset.

conclusionsPatients with early-onset pSS have distinctive clinical manifestations and greater activation of the cellular immune system, present with more severe clinical symptoms and immunological features, have increased activation of circulating T cells and have an unfavourable prognosis. Thus, they require more positive treatment with glucocorticoids and/or immunosuppressants and merit closer follow-up and regular monitoring.

Indexed as

AdultAgedAge FactorsBiomarkersFemaleHumansLymphocytesMaleMiddle AgedPrognosisRetrospective StudiesSeverity of Illness IndexSjogren's SyndromeYoung AdultBiomarkersESSDAIlymphocyte profileonset ageprimary Sjögren’s syndromeprognoses

Identifiers

PMID33878180
PMCPMC8824414
OpenAlexW3153406355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.